Figure 5

Cost effectiveness acceptability curve showing the probability that using RI-HSCT is cost-effective compared with BT-ICT. RI-HSCT: Reduced intensity hematopoietic stem cell transplantation; BT-ICT: Blood transfusion combined with iron chelating therapy.